{
    "2021-03-01": [
        [
            {
                "time": "",
                "original_text": "医药生物行业报告：医药板块大幅调整之后的布局思路",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业报告",
                        "医药板块",
                        "大幅调整",
                        "布局思路"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "东吴证券---医药生物行业：新冠疫苗逐步获批，巨大期权有望加速兑现【行业研究】",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "医药生物",
                        "行业研究",
                        "新冠疫苗",
                        "逐步获批",
                        "巨大期权",
                        "加速兑现"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}